

January 28, 2026

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

Scrip Code: 543349

NSE Symbol: ACUTAAS

Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release discussing the third quarter and nine months ended financial results as on December 31, 2025.

This Press Release will be available on the website of the Company www.acutaas.com.

Kindly take the same on record.

Yours faithfully,
For, ACUTAAS CHEMICALS LIMITED

Ekta Kumari Srivastava
Company Secretary & Compliance Officer



Encl: Press Release

Acutaas Chemicals Limited reports Q3 FY26 Results

Q3 FY26 Revenue from Operation at ₹3,932mn, up 43.0% YoY

Q3 FY26 PAT crosses ₹1,000mn milestone, reaching ₹1,062mn, up 133.7% YoY

Surat, January 28, 2026: Acutaas Chemicals Limited (BSE: 543349, NSE: ACUTAAS), a leading global manufacturer of advance pharmaceutical intermediates and speciality chemicals, today announced financial results for the quarter and nine months ended December 31, 2025.

Consolidated Financial Results – Q3 & 9MFY26:

Particulars (Rs. Mn)	Q3FY26	Q3FY25	YoY	Q2FY26	QoQ	9MFY26	9MFY25	YoY
Revenue from Operations	3,932	2,750	43.0%	3,062	28.4%	9,066	6,984	29.8%
Gross Profit	2,240	1,272	76.1%	1,707	31.2%	5,051	3,087	63.6%
Gross Margin	57.0%	46.2%		55.8%		55.7%	44.2%	
EBITDA	1,507	687	119.4%	953	58.0%	2,969	1,471	101.8%
EBITDA Margin	38.3%	25.0%		31.1%		32.7%	21.1%	
PAT	1,062	454	133.7%	719	47.82%	2,221	977	127.3%
PAT Margin	27.0%	16.5%		23.5%		24.5%	14.0%	

Commenting on results, Mr. Naresh Patel, Executive Chairman & Managing Director, Acutaas Chemicals Limited, said: *“We continue to reinforce our core pharmaceutical intermediates business through the addition of CMO/CDMO opportunities alongside strengthening our business foundation by scaling battery chemicals and semiconductor chemicals verticals. These businesses, which are currently under active capital investment, are progressing steadily toward scale. Over the next three years, we expect each vertical to operate as an independent, self-sustaining growth engine, contributing meaningfully to our overall topline.*

I am pleased to share that we have sustained strong growth momentum in Q3, driven by the continued ramp-up of our CDMO business. As we progress toward the end of the financial year, supported by a healthy order book and improved visibility, we are revising our revenue growth guidance upward—from 25% to approximately 30%.”

PRESS RELEASE

For Immediate dissemination



Key Results & Business Highlights (Q3FY26 Consolidated):

- ✓ **Revenue from operations** for Q3FY26 grew by **43.0% YoY to Rs. 3,932 mn**
- ✓ The **gross margin** for the quarter improved to **57.0%** up 1,073 bps YoY
- ✓ **EBITDA** for the quarter came at **Rs. 1,507 mn** up 119.4% YoY
- ✓ **EBITDA margin** for the quarter was at **38.3%** as compared to 25.0% in Q3FY25
- ✓ **PAT** for the quarter was **Rs. 1,062 mn** up 133.7% as compared to PAT of Rs. 454 mn in Q3FY25
- ✓ The **PAT margin** for the quarter was at **27.0%** up 1,049 bps YoY

ABOUT ACUTAAS CHEMICALS LIMITED:

Acutaas Chemicals Limited is a speciality chemicals manufacturer serving a wide range of industries, including pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. Our core strength lies in the research-driven development and manufacturing of advanced pharmaceutical intermediates used in both regulated and generic APIs, as well as intermediates for New Chemical Entities (NCEs).

We are also expanding our portfolio to include high-value speciality chemicals for emerging technologies such as battery materials, semiconductor, and next-generation electronic applications. In addition, our offerings include parabens and their formulations, methyl salicylate, and niche key starting materials (KSMs) used in cosmetics and other industrial segments.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Acutaas Chemicals Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

PRESS RELEASE

For Immediate dissemination



For details, please contact:

Investor Relations at Acutaas Chemicals Limited

Ekta Srivastava, Company Secretary &
Compliance Officer

cs@acutaas.com

Senior Manager – Investor Relations

Mr. Rahul Thakur

Rahul.thakur@acutaas.com

Registered Office

Plot no. 440/4, 5 & 6, Road No. 82/A,
GIDC Sachin, Surat- 394230

CIN: L24100GJ2007PLC051093

ISIN: INE00FF01025

NSE Code: ACUTAAS

BSE CODE: 543349

Website: www.acutaas.com